Wall Street analyst estimates for Cytokinetics, Incorporated (CYTK): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-1.45 | ||
| 2026-08-06 | $-1.50 | $-1.63 | +8.0% |
| 2026-05-05 | $-1.67 | $-1.67 | +0.0% |
| 2026-02-24 | $-1.50 | $-1.48 | -1.4% |
| 2025-11-05 | $-2.55 | $-1.59 | -60.4% |
| 2025-08-07 | $-1.12 | $-1.34 | +16.4% |
| 2025-05-06 | $-1.36 | $-1.41 | +3.5% |
| 2025-02-27 | $-1.26 | $-1.29 | +2.3% |
Valuation Ratios
| Price / Book | -52.77 |
| EV / EBITDA | -11.34 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.4M | $13.4M | $31.5M | $26.9M | $55.8M | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M |
| Cost of Revenue | $64.4M | $90.3M | $89.1M | $86.1M | $97.0M | $159.9M | $240.8M | $330.1M | $339.4M | $10.1M |
| Gross Profit | $42.0M | -$76.9M | -$57.6M | -$59.3M | -$41.1M | -$89.5M | -$146.2M | -$322.6M | -$320.9M | $77.9M |
| Research & Development | $59.9M | $90.3M | $89.1M | $86.1M | $97.0M | $159.9M | $240.8M | $330.1M | $339.4M | $405.9M |
| Selling, General & Admin | $27.8M | $36.5M | $31.3M | $39.6M | $52.8M | $96.8M | $178.0M | $173.6M | $215.3M | $284.3M |
| Operating Expenses | $23.3M | $36.5M | $31.3M | $39.6M | $52.8M | $96.8M | $178.0M | $173.6M | $215.3M | $690.2M |
| Operating Income | $18.7M | -$113.4M | -$88.9M | -$98.9M | -$93.9M | -$186.3M | -$324.2M | -$496.2M | -$536.2M | -$612.3M |
| EBITDA | $14.9M | -$108.9M | -$83.5M | -$93.0M | -$86.8M | -$176.3M | -$329.4M | -$456.7M | -$493.5M | -$775.3M |
| Interest Expense | $2.2M | $17.0M | $21.6M | $27.4M | $38.7M | $29.3M | $51.2M | $57.7M | $86.5M | $103.9M |
| Pre-tax Income | $16.5M | -$127.8M | -$106.3M | -$121.7M | -$127.3M | -$215.3M | -$389.0M | -$526.2M | -$589.5M | -$785.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | $16.5M | -$127.8M | -$106.3M | -$121.7M | -$127.3M | -$215.3M | -$389.0M | -$526.2M | -$589.5M | -$785.0M |
| EPS | $0.41 | $-2.59 | $-1.95 | $-2.59 | $-1.97 | $-2.80 | $-4.33 | $-5.45 | $-5.26 | $-6.54 |
| EPS (Diluted) | $0.39 | $-2.59 | $-1.95 | $-2.59 | $-1.97 | $-2.80 | $-4.33 | $-5.45 | $-5.26 | $-6.54 |
| Shares Outstanding (Diluted) | $42.6M | $49.4M | $54.4M | $57.6M | $64.5M | $76.9M | $89.8M | $96.5M | $112.0M | $120.1M |
Price
| Price | $69.92 |
| Market Cap | $8.7B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABVX · AXSM · CORT · CRSP · HALO · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of CYTK: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks